Author

Christos Hatzis

Associate Professor Adjunct of Medicine, Yale School of Medicine, Yale Cancer Center - Cited by 9,917 - clinical computational oncology - translational cancer research - next generation sequencing - bioinformatics - cancer heterogeneity
Title
Cited by
Year
SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer
BV Sinn, C Fu, R Lau, J Litton, TH Tsai, R Murthy, A Tam, E Andreopoulou, ...NPJ breast cancer 5 (1), 16, 2019201
123
2019
Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden
T Qing, H Mohsen, M Marczyk, Y Ye, T O’Meara, H Zhao, JP Townsend, ...Nature communications 11 (1), 2438, 2020202
55
2020
Immune profiling of pre-and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
X Li, S Warren, V Pelekanou, V Wali, A Cesano, M Liu, P Danaher, ...Journal for immunotherapy of cancer 7, 1-9, 2019201
46
2019
Long‐term survival of de novo stage IV human epidermal growth receptor 2 (HER2) positive breast cancers treated with HER2‐targeted therapy
Y Wong, AS Raghavendra, C Hatzis, JP Irizarry, T Vega, N Horowitz, ...The Oncologist 24 (3), 313-318, 2019201
44
2019
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women
T O’Meara, A Safonov, D Casadevall, T Qing, A Silber, B Killelea, C Hatzis, ...Breast cancer research and treatment 175, 247-259, 2019201
43
2019
The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues
M Marczyk, C Fu, R Lau, L Du, AJ Trevarton, BV Sinn, RE Gould, ...BMC cancer 19, 1-12, 2019201
32
2019
The impact of communication style on patient satisfaction
AA Trant, B Szekely, SS Mougalian, MP DiGiovanna, T Sanft, E Hofstatter, ...Breast cancer research and treatment 176, 349-356, 2019201
23
2019
Identification and validation of a novel biologics target in triple negative breast cancer
VB Wali, GA Patwardhan, V Pelekanou, T Karn, J Cao, A Ocana, Q Yan, ...Scientific reports 9 (1), 14934, 202
19
2019
The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer
D Cibula, L Dostálek, J Jarkovsky, CH Mom, A Lopez, H Falconer, ...European journal of cancer 158, 111-122, 2021202
14
2021
Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations
GA Patwardhan, M Marczyk, VB Wali, DF Stern, L Pusztai, C HatzisNPJ Breast Cancer 7 (1), 60, 2021202
13
2021
Breast cancer patients with brain metastasis undergoing GKRS
M Abu-Khalaf, S Muralikrishnan, C Hatzis, D Canchi, JB Yu, V ChiangBreast Cancer 26, 147-153, 2019201
12
2019
Increasing accrual of minority patients in breast cancer clinical trials
AA Trant, L Walz, W Allen, J DeJesus, C Hatzis, A SilberBreast Cancer Research and Treatment 184, 499-505, 2020202
12
2020
Multi-omics investigation of innate navitoclax resistance in triple-negative breast cancer cells
M Marczyk, GA Patwardhan, J Zhao, R Qu, X Li, VB Wali, AK Gupta, ...Cancers 12 (9), 2551, 2020202
10
2020
Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy
MM Abu-Khalaf, A Safonov, J Stratton, S Wang, C Hatzis, E Park, ...Breast Cancer Research and Treatment 176, 261-270, 2019201
10
2019
A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making
T Sanft, A Berkowitz, B Schroeder, C Hatzis, CA Schnabel, A Brufsky, ...Breast Cancer Management 8 (1), BMT22, 2019201
10
2019
Analysis of pre-and posttreatment tissues from the SWOG S0800 trial reveals an effect of neoadjuvant chemotherapy on the breast cancer genome
Analysis of pre-and posttreatment tissues from the SWOG S000 trial reveals an effect of neoadjuvant chemotherapy on the breast cancer genomeRL Powles, VB Wali, X Li, WE Barlow, Z Nahleh, AM Thompson, ...Clinical Cancer Research 26 (), 1977-194, 2020202
8
2020
Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers
X Li, S Kumar, A Harmanci, S Li, RR Kitchen, Y Zhang, VB Wali, ...Genome medicine 13 (1), 70, 2021202
6
2021
Abstract P5-13-02: neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer …
MM Abu-Khalaf, K Aderhold, M Marczyk, G Chung, E Hofstatter, T Sanft, ...Cancer Research 80 (_Supplement), P5-13-02-P5-13-02, 2020202
4
2020
Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples
C Fu, M Marczyk, M Samuels, AJ Trevarton, J Qu, R Lau, L Du, T Pappas, ...BMC cancer 21 (1), 1-10, 2021202
3
2021
Comprehensive analysis of metabolic isozyme targets in cancer
M Marczyk, V Gunasekharan, D Casadevall, T Qing, J Foldi, R Sehgal, ...Cancer Research 82 (9), 1698-1711, 2022202
3
2022

Referred From: https://scholar.google.com/citations?user=5HQ6T9QAAAAJ&hl=en

Cited by
Citations 9917
h-index 45
i10-index 95
Open Access Journals